Business Context and Reporting Period
This Form 8-K Current Report was filed by Aytu BioScience, Inc. on April 18, 2019, covering events that occurred on April 15, 2019. The filing details the renewal of executive employment agreements and changes to the Board of Directors and committee leadership.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes and Executive Compensation
The Board renewed the employment agreements for two key executives, effective April 15, 2019, with terms extending for 24 months:
- Joshua R. Disbrow (CEO): Annual base salary of $330,000; annual discretionary bonus target of 125% of base salary; and restricted stock or options to be granted on or after August 1, 2019.
- Jarrett T. Disbrow (COO): Annual base salary of $250,000; annual discretionary bonus target of 125% of base salary; and restricted stock or options to be granted on or after August 1, 2019.
Board and Committee Changes
Significant changes to the Board of Directors and committee assignments were announced:
- New Director: Steven J. Boyd was appointed to the Board to fill a vacancy. He is the founder and Chief Investment Officer of Armistice Capital, LLC. He has elected to receive no compensation for his Board service.
- Committee Resignations: Gary Cantrell resigned as Chairman of the Compensation Committee and as a member of the Audit Committee. He remains a member of the Compensation Committee.
- Committee Appointments: Michael Macaluso was appointed to the Audit Committee and the Compensation Committee. He was also appointed as the new Chairman of the Compensation Committee.
Outlook and Risks
The filing does not provide specific financial guidance, outlook, or risk factors. It notes that the full text of the employment agreements will be filed as exhibits to the Quarterly Report on Form 10-Q for the quarter ending March 31, 2019.
Key Facts for Investor Verification
- Verify the total potential compensation liability for the CEO and COO based on the 125% bonus targets and future equity grants.
- Confirm the specific terms of the employment agreements once filed as exhibits to the Form 10-Q.
- Monitor the impact of the new Board member, Steven J. Boyd, on strategic direction given his background in healthcare-focused hedge funds.
- Review the composition of the Audit and Compensation Committees following the leadership changes.